[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_98":99},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","tvmbpiwrlagpt9obonqrgm8p6","revision",2,"title","ImmuCell Corporation 2026年第三季度产品销售额同比增长46%","originalTitle","8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)","summary","ImmuCell Corporation 2026年第三季度产品销售额同比增长46%。该数据基于截至2026年9月30日的初步未审计结果。公司已发布相关财报公告。","reason","source",{"_11":88,"_89":90,"_91":92,"_93":57,"_94":95,"_96":97},"links",{"_85":86,"_63":87},"publishedAt","2026-10-13T10:01:58.000Z","discoveredAt","2026-10-13T10:07:09.003Z","timelineAt","category","ai-products","tags",[81,82,83,84],"stockSymbols",[80],"score",42,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fuoS6z0eO8nU",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","73f36723-07a9-4bdb-b6ac-b25f5da34204","ImmuCell 2026年Q3产品销售额同比增长46%",{"_72":73,"_15":74},"zh","

UNITED STATES\n

SECURITIES AND EXCHANGE COMMISSION\n

Washington, D.C. 20549\n

FORM 8-K\n

CURRENT REPORT\n

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934\n

Date of Report (Date of earliest event reported) October 12, 2026\n

\n\n \n \n \n \n\n

ImmuCell Corporation

(Exact name of registrant as specified in its charter)

\n\n \n \n \n \n\n

DE		001-12934		01-0382980
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

\n\n \n \n \n \n\n

56 Evergreen Drive Portland, Maine		04103
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code 207-878-2770\n

\n\n \n \n \n \n\n

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K ﬁling is intended to simultaneously satisfy the ﬁling obligation of the Registrant under any of the following provisions:

\n\n \n \n\n

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

\n\n \n \n\n

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

\n\n \n \n\n

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

\n\n \n \n\n

☐	Pre-commencement communications

Securities registered pursuant to Section 12(b) of the Act:

\n\n \n \n \n \n\n

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.10 par value per share		ICCC		The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐\n

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02. Results of Operations and Financial Condition\n

On October 12, 2026 ImmuCell Corporation (the \"Company\") issued a press release announcing a 46% increase in product sales in quarter three of 2026 as compared to quarter three of 2025, based on preliminary, unaudited sales results for the quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information shall not be deemed \"filed\" for purposes of Section 18 of the Securities Exchange Act of 1934 (the \"Exchange Act\") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Exhibits.\n

(d) Exhibits.

\n\n \n \n \n \n\n

	99.1	Press Release of the Company dated October 12, 2026
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE\n

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

\n\n \n \n \n \n \n \n \n \n \n \n\n

	IMMUCELL CORPORATION

Date: October 13, 2026	By:	/s/ Timothy C. Fiori
		Timothy C. Fiori
		Chief Financial Officer

Exhibit Index\n

\n\n \n \n \n \n \n \n\n

Exhibit No.	Description
99.1	99.1 Press Release of the Company dated October 12, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

","zhKind","complete","ICCC","政策与监管","财报","业绩指引","公司与财报","aihot","/items/tvmbpiwrlagpt9obonqrgm8p6","https://www.sec.gov/Archives/edgar/data/811641/000143774926032465/0001437749-26-032465-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792108800&sig=e4adf00b596060d2","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792108800&sig=208b33ec2756b0ea 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792108800&sig=786fcd6a5ff8379c 96w","changelogVersion","2026-10-01T08:00"]